Oramed Pharmaceuticals / USA
台灣醫療科技展展位:
ABOUT US
Oramed Pharmaceuticals (NASDAQ: ORMP) has developed an innovative technology to transform injectable treatments into oral therapies.

Oramed’s flagship product, an oral insulin capsule, has the potential to better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles.

Oramed’s oral insulin is currently in advanced clinical trials under the US FDA for both type 1 and type 2 diabetes.

In addition to oral insulin, the company’s proprietary POD™ technology can be used to orally administer a number of protein-based therapies, which are available only via injection.
 
成立時間2006
資本額USD 740.996M
員工數10
產品/服務類別
生技製藥 預防醫學
採購與合作需求項目
n/a
供應與銷售項目
n/a
研發技術
Diabetes is a chronic condition characterized by hyperglycemia, or elevated blood glucose levels. If left untreated, diabetes may lead to complications such as cardiovascular disease, chronic renal failure, retinopathy and amputations.



Type 2 diabetes (T2DM) is a progressive disease characterized by impaired ß cell function and insulin resistance. There are over 460 million type 2 diabetics worldwide with an economic burden of more than half a trillion dollars annually.



Orally administered insulin should bring with it enhanced patient compliance. In addition, intestinally absorbed-oral insulin actually mimics insulin’s natural location and gradients in the body by first passing through the liver before entering the bloodstream.



Oramed’s oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment, potentially slowing disease progression and delaying or even eliminating late-stage complications.
應用範疇
n/a
特色優勢
n/a
產品/服務類別
生技製藥 科研機構
最新商機情報
你可能有興趣的產品服務
你可能有興趣的機構/企業
© Institute for Biotechnology and Medicine Industry & Research Center for Biotechnology and Medicine Policy
聯絡我們
Loading...